Condition: Neuroblastoma · GD2 Antibody (Naxitamab) · Sponsor: Guangzhou Women and Children's Medical Center
To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.
This description comes directly from the study's public registry record.
Wenyue Si, Bachelor · +86-(020)-38367270 · feky@gwcmc.org
Always discuss trial participation with your own doctor first.
| Guangzhou Women And Children's Medical Center | Guanzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06574698